Bronchial reversibility with a short-acting β2-agonist predicts the FEV1 response to administration of a long-acting β2-agonist with inhaled corticosteroids in patients with bronchial asthma

Ohwada,Akihiko; Inami,Kei; Onuma,Emi; Matsumoto‑Yamazaki,Mariko; Atsuta,Ryo; Takahashi,Kazuhisa

doi:10.3892/etm.2011.268

July-August 2011 Volume 2 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-August 2011 Volume 2 Issue 4

Full Size Image

Article Open Access

Bronchial reversibility with a short-acting β2-agonist predicts the FEV1 response to administration of a long-acting β2-agonist with inhaled corticosteroids in patients with bronchial asthma

Authors:
- Akihiko Ohwada
- Kei Inami
- Emi Onuma
- Mariko Matsumoto‑Yamazaki
- Ryo Atsuta
- Kazuhisa Takahashi
View Affiliations / Copyright

Affiliations: Ohwada Clinic, Ichikawa, Chiba 272-0023, Japan, Department of Respiratory Medicine, Juntendo University School of Medicine, Tokyo, Japan
Pages: 619-623
|
Published online on: May 12, 2011

https://doi.org/10.3892/etm.2011.268
Expand metrics +

Abstract

A long-acting β2-agonist (LABA) combined with an inhaled corticosteroid (ICS) is frequently prescribed as initial therapy in steroid-naïve asthma patients because of its effective control of symptoms and improvement of pulmonary function. However, it is unclear which patients will be responsive to LABAs and whether bronchial responsiveness to LABAs is similar to that to short-acting β2-agonists (SABAs) in a clinical setting. Therefore, the goal of the present study was to compare the changes in spirometric parameters after SABA (salbutamol) inhalation to those after 1-month LABA/ICS (salmeterol/fluticasone propionate) therapy. Spirometric changes were evaluated as absolute values, as the percentage of predicted normal values and as the percentage of baseline values after salbutamol inhalation or 1-month LABA/ICS therapy in 45 patients with asthma. Compared to SABA inhalation, LABA/ICS therapy produced significant improvements in forced expiratory volume in 1 sec (FEV1), peak expiratory flow (PEF), forced expiratory flow at 50% of vital capacity expired (FEF50%) from baseline (expressed as the percentage predicted) in all patients. FEV1 and the FEV1/forced vital capacity (FVC) ratio after SABA or LABA/ICS therapy were inversely related to the corresponding baseline values. Analysis of spirometric changes after SABA inhalation showed that FEV1 was the best among spirometric parameters, such as PEF, correlated with responsiveness to LABA/ICS therapy. Reversibility of FEV1 with SABA inhalation predicts the spirometric response to LABA/ICS as initial therapy in patients with bronchial asthma. LABA/ICS therapy had a greater effect on bronchial reversibility in asthmatic patients, compared to SABA inhalation. This suggested that evaluation of bronchial reversibility after LABA/ICS therapy would be superior to that after SABA inhalation.

View Figures

View References

1.	Global Initiative for Asthma (GINA): Global strategy for asthma management and prevention. NHLBI/WHO Workshop Report. Bethesda: National Institutes of Health, National Heart, Lung and Blood Institute, Upgrade; 2009
2.	Ni Chroinin M, Greenstone I, Lasserson TJ and Ducharme FM: Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst Rev. 7:CD0053072009.
3.	Pellegrino R, Viegi G, Brusasco V, et al: Interpretative strategies for lung function tests. Eur Respir J. 26:948–968. 2005. View Article : Google Scholar : PubMed/NCBI
4.	Miller MR, Hankinson J, Brusasco V, et al: Standardisation of spirometry. Eur Respir J. 26:319–338. 2005. View Article : Google Scholar : PubMed/NCBI
5.	American Thoracic Society: Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis. 144:1202–1218. 1991. View Article : Google Scholar : PubMed/NCBI
6.	Lehtimäki L, Kankaanranta H, Saarelainen S, Turjanmaa V and Moilanen E: Peripheral inflammation in patients with asthmatic symptoms but normal lung function. J Asthma. 42:605–609. 2005.PubMed/NCBI
7.	Nelson HS, Weiss ST, Bleecker ER, Yancey SW and Dorinsky PM; SMART Study Group: The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 129:15–26. 2006. View Article : Google Scholar
8.	Chowdhury BA and Pan GD: The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med. 362:1169–1171. 2010. View Article : Google Scholar : PubMed/NCBI
9.	Dobashi K: Epidemiology of asthma. Igaku-No-Ayumi. 233:5–12. 2010.(In Japanese).
10.	Chatenoud L, Malvezzi M, Pitrelli A, La Vecchia C and Bamfi F: Asthma mortality and long-acting beta2-agonists in five major European countries, 1994–2004. J Asthma. 46:546–551. 2009.PubMed/NCBI
11.	Brand PL, Quanjer PH, Postma DS, et al: Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group. Thorax. 47:429–436. 1992. View Article : Google Scholar : PubMed/NCBI
12.	Beach JR, Young CL, Stenton SC, Avery AJ, Walters EH and Hendrick DJ: A comparison of the speeds of action of salmeterol and salbutamol in reversing methacholine-induced bronchoconstriction. Pulm Pharmacol. 5:133–135. 1992. View Article : Google Scholar : PubMed/NCBI
13.	Yancey SW and Ortega HG: Retrospective characterization of airway reversibility in patients with asthma responsive to bronchodilators. Curr Med Res Opin. 23:3205–3207. 2007. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Bronchial reversibility with a short-acting β2-agonist predicts the FEV1 response to administration of a long-acting β2-agonist with inhaled corticosteroids in patients with bronchial asthma

This article is mentioned in:

Abstract

Related Articles